[go: up one dir, main page]

SV2006002169A - Moduladores androgenos ref. pc32396a - Google Patents

Moduladores androgenos ref. pc32396a

Info

Publication number
SV2006002169A
SV2006002169A SV2005002169A SV2005002169A SV2006002169A SV 2006002169 A SV2006002169 A SV 2006002169A SV 2005002169 A SV2005002169 A SV 2005002169A SV 2005002169 A SV2005002169 A SV 2005002169A SV 2006002169 A SV2006002169 A SV 2006002169A
Authority
SV
El Salvador
Prior art keywords
pc32396a
ref
modulators
androgen modulators
androgen
Prior art date
Application number
SV2005002169A
Other languages
English (en)
Inventor
Boys Mark Laurence
Victoria Leigh Downs
Daniel Yunlong Du
William Glen Harter
Lain-Yen Hu
Donna Michele Iula
Huangshu Lei
Bruce Allen Lefker
Yvonne Dorothy Smith
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2006002169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV2006002169A publication Critical patent/SV2006002169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A UNA NUEVA CLASE DE 4-CICLOALCOXIBENZONITRILOS Y A SU USO COMO MODULADORES DEL RECEPTOR DE ANDRÓGENOS. OTROS ASPECTOS DE LA INVENCIÓN ESTÁN DIRIGIDOS AL USO DE ESTOS COMPUESTOS PARA DISMINUIR LA SECRECIÓN DE SEBO Y PARA ESTIMULAR EL CRECIMIENTO CAPILAR
SV2005002169A 2004-07-08 2005-07-08 Moduladores androgenos ref. pc32396a SV2006002169A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58616004P 2004-07-08 2004-07-08
US59803304P 2004-08-02 2004-08-02

Publications (1)

Publication Number Publication Date
SV2006002169A true SV2006002169A (es) 2006-02-15

Family

ID=35079243

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002169A SV2006002169A (es) 2004-07-08 2005-07-08 Moduladores androgenos ref. pc32396a

Country Status (15)

Country Link
US (2) US7670613B2 (es)
EP (1) EP1781598A1 (es)
JP (1) JP4874965B2 (es)
AR (1) AR049965A1 (es)
BR (1) BRPI0513020A (es)
CA (1) CA2570047C (es)
GT (1) GT200500187A (es)
MX (1) MXPA06015169A (es)
NL (1) NL1029457C2 (es)
PA (1) PA8639001A1 (es)
PE (1) PE20060379A1 (es)
SV (1) SV2006002169A (es)
TW (1) TW200605876A (es)
UY (1) UY29008A1 (es)
WO (1) WO2006006065A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
US20080064745A1 (en) * 2004-08-18 2008-03-13 Warner-Lambert Company Llc Androgen Modulators
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP2396727A1 (en) * 2009-02-13 2011-12-21 Peter Anthony Crosby Memory utilization analysis
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
EP3484462B1 (en) 2016-07-15 2022-12-14 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
ES2945224T3 (es) 2016-10-11 2023-06-29 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
CA3165168A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA3181782A1 (en) 2020-05-09 2021-11-18 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
US3535365A (en) * 1967-11-29 1970-10-20 Merck & Co Inc Preparation of 2,6-dichloro-4-methoxy-benzonitrile
SU469247A3 (ru) 1972-01-14 1975-04-30 Майлз Лабораториз Инк (Фирма) Способ получени производных хромона
US4029493A (en) * 1973-02-23 1977-06-14 Mobil Oil Corporation Substituted phenoxybenzonitriles as herbicides
FR2397387A1 (fr) * 1976-04-27 1979-02-09 Serobiologiques Lab Sa 4,4'-bis-formyl-polyhalo-diphenoxyalcanes, procede de preparation et application a la synthese de 4,4'-dicyano-polyhalo-diphenoxyalcanes
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4567201A (en) 1981-11-25 1986-01-28 Takeda Chemical Industries, Ltd. Diphenoxypropane derivatives and compositions of antiasthmatic and antiinflammatory agents thereof
GB8504093D0 (en) 1985-02-18 1985-03-20 Ici Plc Alkene alkyne/cycloalkylene derivatives
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
EP0107759B1 (de) * 1982-08-26 1992-12-16 MERCK PATENT GmbH Cyclohexanderivate und ihre Verwendung als Komponenten Flüssigkristalliner-Dielektrika
JPS59144747A (ja) 1983-02-04 1984-08-18 Chisso Corp ２−クロロ−４−アルキルオキシベンゾニトリル化合物
US4536321A (en) * 1983-02-18 1985-08-20 Chisso Corporation Fluorobenzene derivatives and liquid crystal compositions containing the same
JPS63227502A (ja) 1987-03-17 1988-09-21 Sds Biotech Kk 防菌防カビ剤
US4992433A (en) * 1987-11-23 1991-02-12 Janssen Pharmaceutica N.V. Novel pyridazinamine derivatives
US4925590A (en) * 1988-03-10 1990-05-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Derivatives of 4-cyano-2,3-difluorophenol
DE3825170A1 (de) 1988-07-23 1990-01-25 Hoechst Ag, 65929 Frankfurt Substituierte 5-(4-(4,5-dihydro-2-oxazolyl)-phenoxyalkylenoxyalkyl)-isoxazole, verfahren sowie 5-(phenoxyalkylenoxyalkyl)-isoxazole als zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekaempfung von krankheiten, die durch infektion mit viren hervorgerufen wurden
DE4017019A1 (de) 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
JPH04124183A (ja) 1990-09-14 1992-04-24 Mitsubishi Rayon Co Ltd 光学活性パントラクトン誘導体
JP3088777B2 (ja) 1991-03-27 2000-09-18 富士薬品工業株式会社 新規光学分割剤及びそれを用いる光学活性アミンの製造方法
JP3151929B2 (ja) 1992-05-15 2001-04-03 大日本インキ化学工業株式会社 フルオロシクロヘキセン誘導体
DE4217928A1 (de) 1992-05-30 1993-12-02 Hoechst Ag Neue Mischungen aus Herbiziden und Antidots, neue (Hetero-)Aryloxy-Verbindungen, Verfahren zu deren Herstellung, diese enthaltenden Mittel und deren Verwendung
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
US5455274A (en) 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
US5316755A (en) * 1993-02-02 1994-05-31 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract
GB2278054A (en) 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
TW262553B (es) * 1994-03-17 1995-11-11 Hitachi Seisakusyo Kk
CN1147206A (zh) 1994-04-21 1997-04-09 耐克麦德英梅金公司 含有药用粘土的x-射线造影组合物
JPH07309850A (ja) 1994-05-16 1995-11-28 Canon Inc 光学活性化合物、それを含有する液晶組成物、それを有する液晶素子及びそれらを用いた表示方法、表示装置
EP0684235A1 (en) 1994-05-27 1995-11-29 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
DE69524528T2 (de) 1994-10-14 2002-08-01 Merck Patent Gmbh ZNS wirksames (R)-(-)-2-[5-(4-Fluorophenyl)-3-pyridylmethylaminomethyl]chroman
JP3802581B2 (ja) * 1995-03-01 2006-07-26 富山化学工業株式会社 新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
JPH0953018A (ja) * 1995-06-09 1997-02-25 Mitsubishi Chem Corp フタロシアニン誘導体及び該誘導体を使用した光学記録媒体
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19534209A1 (de) * 1995-09-15 1997-03-20 Jenapharm Gmbh Hormonales Mittel zur Behandlung der Haut
ES2127106B1 (es) * 1996-03-21 1999-11-16 Menarini Lab Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.
US5847166A (en) * 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
WO1998033779A1 (en) 1997-02-04 1998-08-06 Dong Wha Pharm. Ind. Co., Ltd. 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
US6013668A (en) 1997-08-13 2000-01-11 Bristol-Myers Squibb Company Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino]methyl]amino]benzonitrile
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
CN1391576A (zh) * 1999-08-27 2003-01-15 利甘德药品公司 雄激素受体调节剂化合物及方法
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
EP1299334B1 (en) 2000-07-13 2008-01-16 MERCK PATENT GmbH Chiral compounds i
DE60124322T2 (de) * 2000-08-24 2007-05-31 University Of Tennessee Research Foundation, Knoxville Selektive modulatoren des androgenrezeptors und methoden zu deren verwendung
EP1313701A1 (en) 2000-08-31 2003-05-28 Pfizer Limited Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
EP1317419B1 (en) * 2000-09-06 2009-04-22 Emisphere Technologies, Inc. Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
TWI290919B (en) 2000-10-06 2007-12-11 Tanabe Seiyaku Co Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same
US6646012B2 (en) 2001-01-16 2003-11-11 Theravance, Inc. Sodium channel modulators
CZ20031902A3 (cs) 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4
JP3806090B2 (ja) 2001-04-10 2006-08-09 ファイザー・インク Ｈｉｖ関連疾患治療用のピラゾール誘導体
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
CN1646115B (zh) 2002-02-07 2010-06-09 Gtx公司 Sarms在制备用于治疗良性前列腺增生的药物中的应用
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
ATE345125T1 (de) 2002-02-15 2006-12-15 Endorech Inc Biphenylderivate und ihre verwendung als antiandrogene
JP2005519111A (ja) 2002-02-28 2005-06-30 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション 不可逆型選択的アンドロゲンレセプタ修飾因子及びその使用方法
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
DE10218963A1 (de) * 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
US6875438B2 (en) * 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
US7582230B2 (en) 2002-08-14 2009-09-01 Ciba Specialty Chemicals Corporation Liquid crystal display and colour filter with improved transparency for green light
CA2495756A1 (en) 2002-08-26 2004-03-04 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
WO2004026822A2 (en) * 2002-09-19 2004-04-01 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2004110994A1 (en) 2003-06-18 2004-12-23 Pfizer Products Inc. Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
WO2005013914A2 (en) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20070129409A1 (en) 2003-11-20 2007-06-07 Lain-Yen Hu Androgen receptor modulators
JP3997255B2 (ja) * 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
EA011021B1 (ru) 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
US20080064745A1 (en) 2004-08-18 2008-03-13 Warner-Lambert Company Llc Androgen Modulators
CA2578194A1 (en) 2004-08-31 2006-03-09 Stephen Douglas Barrett Androgen modulators
PL1807072T3 (pl) 2004-10-29 2009-06-30 Lilly Co Eli Cykloalkilowe pochodne laktamów jako inhibitory 11-ß-HSD1
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators

Also Published As

Publication number Publication date
AR049965A1 (es) 2006-09-20
PE20060379A1 (es) 2006-05-27
NL1029457C2 (nl) 2006-08-02
EP1781598A1 (en) 2007-05-09
BRPI0513020A (pt) 2008-04-22
JP2008505880A (ja) 2008-02-28
NL1029457A1 (nl) 2006-01-10
MXPA06015169A (es) 2007-08-21
JP4874965B2 (ja) 2012-02-15
US7670613B2 (en) 2010-03-02
WO2006006065A1 (en) 2006-01-19
UY29008A1 (es) 2006-03-31
CA2570047A1 (en) 2006-01-19
TW200605876A (en) 2006-02-16
US20060009427A1 (en) 2006-01-12
PA8639001A1 (es) 2006-06-02
GT200500187A (es) 2006-02-17
CA2570047C (en) 2010-09-28
US20100048517A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
SV2006002169A (es) Moduladores androgenos ref. pc32396a
HN2004000446A (es) Derivados del tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorio
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
GT200800209A (es) Compuestos organicos
UY32996A (es) Antagonistas del receptor crth2 basados en indol
ECSP088648A (es) Nuevos bencimidazoles 2-sustituidos como moduladores de receptor de androgeno selectivos (sarms)
SV2008002986A (es) Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207
EA201100055A1 (ru) Усиленные полиамином составы для ионтофореза соединения триптана
CR9649A (es) Aminopirimidinas como modulares de cinasa
HN2012000269A (es) Derivados de ni-acil-5-fluoropirimidinona
CR9496A (es) Moduladores de androgenos
ECSP12011652A (es) Derivados de 5-fluoro-2-oxopirimidinona-1 (2h)-carboxamida substituida-n1
MX2007001993A (es) Moduladores de androgenos.
ECSP066761A (es) Moduladores de receptores de androgenos
IL181447A0 (en) Androgen modulators
EA201101195A1 (ru) Производные розувастатина и аторвастатина
CR8687A (es) Nuevos imidazoles
PE20110406A1 (es) Moduladores de los canales de iones de calcio y sus usos
WO2007017754A3 (en) Androgen modulators
CO6541615A2 (es) Tiazoles bicíclicos como moduladores alostéricos de receptores mglur5
DOP2005000129A (es) Moduladores de androgenos
ECSP088533A (es) Moduladores de estrógeno
ECSP12012047A (es) Derivados de 2-aldoximino-5-fluoropirimidina
GT200500196A (es) Derivados de 4-arilmorfolin-3-ona, su preparacion y su aplicacion en terapeutica
GT200500024A (es) Moduladores de receptores de androgenos

Legal Events

Date Code Title Description
FD Lapse